Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1729 to 1734 of 1734 entries
Sorted by: Best Match Show Resources per page
Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays.

Veterinary sciences

Oungsakul P, Choi E, Shah AK, Mohamed A, O'Leary C, Duffy D, Hill MM, Bielefeldt-Ohmann H.
PMID: 33673507
Vet Sci. 2021 Feb 27;8(3). doi: 10.3390/vetsci8030038.

Visceral hemangiosarcoma (HSA) is one of the more frequent cancers in dogs and has a high metastatic rate and poor prognosis, as clinical signs only become apparent in advanced stages of tumor development. In order to improve early and...

Cite
Oungsakul P, Choi E, Shah AK, et al. Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays. Vet Sci. 2021;8(3)doi: 10.3390/vetsci8030038.
Oungsakul, P., Choi, E., Shah, A. K., Mohamed, A., O'Leary, C., Duffy, D., Hill, M. M., & Bielefeldt-Ohmann, H. (2021). Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays. Veterinary sciences, 8(3), . https://doi.org/10.3390/vetsci8030038
Oungsakul, Patharee, et al. "Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays." Veterinary sciences vol. 8,3 (2021). doi: https://doi.org/10.3390/vetsci8030038
Oungsakul P, Choi E, Shah AK, Mohamed A, O'Leary C, Duffy D, Hill MM, Bielefeldt-Ohmann H. Candidate Glycoprotein Biomarkers for Canine Visceral Hemangiosarcoma and Validation Using Semi-Quantitative Lectin/Immunohistochemical Assays. Vet Sci. 2021 Feb 27;8(3). doi: 10.3390/vetsci8030038. PMID: 33673507; PMCID: PMC7997418.
Copy Download .nbib Format: NLM
L'évaluation et la prise en charge de la paralysie néonatale du plexus brachial.

Paediatrics & child health

Shah V, Coroneos CJ, Ng E.
PMID: 34992703
Paediatr Child Health. 2021 Dec 27;26(8):498-503. doi: 10.1093/pch/pxab082. eCollection 2021 Dec.

La paralysie néonatale du plexus brachial, qui se manifeste à la naissance, peut être débilitante et avoir des conséquences prolongées. La présentation à la naissance dépend de l'importance de la lésion nerveuse et peut varier entre une faiblesse transitoire...

Cite
Shah V, Coroneos CJ, Ng E. L'évaluation et la prise en charge de la paralysie néonatale du plexus brachial. Paediatr Child Health. 2021;26(8):498-503doi: 10.1093/pch/pxab082.
Shah, V., Coroneos, C. J., & Ng, E. (2021). L'évaluation et la prise en charge de la paralysie néonatale du plexus brachial. Paediatrics & child health, 26(8), 498-503. https://doi.org/10.1093/pch/pxab082
Shah, Vibhuti, et al. "L'évaluation et la prise en charge de la paralysie néonatale du plexus brachial." Paediatrics & child health vol. 26,8 (2021): 498-503. doi: https://doi.org/10.1093/pch/pxab082
Shah V, Coroneos CJ, Ng E. L'évaluation et la prise en charge de la paralysie néonatale du plexus brachial. Paediatr Child Health. 2021 Dec 27;26(8):498-503. doi: 10.1093/pch/pxab082. eCollection 2021 Dec. PMID: 34992703; PMCID: PMC8711581.
Copy Download .nbib Format: NLM
A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.

Annals of the New York Academy of Sciences

Klein K, Borchard G, Shah VP, Flühmann B, McNeil SE, de Vlieger JSB.
PMID: 34296458
Ann N Y Acad Sci. 2021 Oct;1502(1):5-13. doi: 10.1111/nyas.14662. Epub 2021 Jul 22.

The diverse nature of complex drug products poses challenges for the development of regulatory guidelines for generic versions. While complexity is not new in medicines, the technical capacity to measure and analyze data has increased. This requires a determination...

Cite
Klein K, Borchard G, Shah VP, et al. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann N Y Acad Sci. 2021;1502(1):5-13doi: 10.1111/nyas.14662.
Klein, K., Borchard, G., Shah, V. P., Flühmann, B., McNeil, S. E., & de Vlieger, J. S. B. (2021). A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Annals of the New York Academy of Sciences, 1502(1), 5-13. https://doi.org/10.1111/nyas.14662
Klein, Kevin, et al. "A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways." Annals of the New York Academy of Sciences vol. 1502,1 (2021): 5-13. doi: https://doi.org/10.1111/nyas.14662
Klein K, Borchard G, Shah VP, Flühmann B, McNeil SE, de Vlieger JSB. A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Ann N Y Acad Sci. 2021 Oct;1502(1):5-13. doi: 10.1111/nyas.14662. Epub 2021 Jul 22. PMID: 34296458; PMCID: PMC8597169.
Copy Download .nbib Format: NLM
Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials.

American journal of cardiovascular disease

Shoar S, Shah AA, Ikram W, Farooq N, Udoh A, Tabibzadeh E, Khavandi S, Khavandi S.
PMID: 34322297
Am J Cardiovasc Dis. 2021 Jun 15;11(3):262-272. eCollection 2021.

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in improving cardiovascular outcome in patients with heart failure (HF) and diabetes mellitus (DM). Although these benefits have been confirmed by several meta-analyses, small studies have not been included into...

Cite
Shoar S, Shah AA, Ikram W, et al. Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. Am J Cardiovasc Dis. 2021;11(3):262-272
Shoar, S., Shah, A. A., Ikram, W., Farooq, N., Udoh, A., Tabibzadeh, E., Khavandi, S., & Khavandi, S. (2021). Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. American journal of cardiovascular disease, 11(3), 262-272.
Shoar, Saeed, et al. "Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials." American journal of cardiovascular disease vol. 11,3 (2021): 262-272.
Shoar S, Shah AA, Ikram W, Farooq N, Udoh A, Tabibzadeh E, Khavandi S, Khavandi S. Cardiovascular benefits of SGLT2 inhibitors in patients with heart failure: a meta-analysis of small and large randomized controlled trials. Am J Cardiovasc Dis. 2021 Jun 15;11(3):262-272. eCollection 2021. PMID: 34322297; PMCID: PMC8303041.
Copy Download .nbib Format: NLM
A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.

Molecular cancer therapeutics

Shah AT, Azad TD, Breese MR, Chabon JJ, Hamilton EG, Straessler K, Kurtz DM, Leung SG, Spillinger A, Liu HY, Behroozfard IH, Wittber FM, Hazard FK, Cho SJ, Daldrup-Link HE, Vo KT, Rangaswami A, Pribnow A, Spunt SL, Lacayo NJ, Diehn M, Alizadeh AA, Sweet-Cordero EA.
PMID: 34353895
Mol Cancer Ther. 2021 Oct;20(10):2016-2025. doi: 10.1158/1535-7163.MCT-20-0987. Epub 2021 Aug 05.

Most circulating tumor DNA (ctDNA) assays are designed to detect recurrent mutations. Pediatric sarcomas share few recurrent mutations but rather are characterized by translocations and copy-number changes. We applied Cancer Personalized Profiling by deep Sequencing (CAPP-Seq) for detection of...

Cite
Shah AT, Azad TD, Breese MR, et al. A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Mol Cancer Ther. 2021;20(10):2016-2025doi: 10.1158/1535-7163.MCT-20-0987.
Shah, A. T., Azad, T. D., Breese, M. R., Chabon, J. J., Hamilton, E. G., Straessler, K., Kurtz, D. M., Leung, S. G., Spillinger, A., Liu, H. Y., Behroozfard, I. H., Wittber, F. M., Hazard, F. K., Cho, S. J., Daldrup-Link, H. E., Vo, K. T., Rangaswami, A., Pribnow, A., Spunt, S. L., Lacayo, N. J., Diehn, M., Alizadeh, A. A., & Sweet-Cordero, E. A. (2021). A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Molecular cancer therapeutics, 20(10), 2016-2025. https://doi.org/10.1158/1535-7163.MCT-20-0987
Shah, Avanthi Tayi, et al. "A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas." Molecular cancer therapeutics vol. 20,10 (2021): 2016-2025. doi: https://doi.org/10.1158/1535-7163.MCT-20-0987
Shah AT, Azad TD, Breese MR, Chabon JJ, Hamilton EG, Straessler K, Kurtz DM, Leung SG, Spillinger A, Liu HY, Behroozfard IH, Wittber FM, Hazard FK, Cho SJ, Daldrup-Link HE, Vo KT, Rangaswami A, Pribnow A, Spunt SL, Lacayo NJ, Diehn M, Alizadeh AA, Sweet-Cordero EA. A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas. Mol Cancer Ther. 2021 Oct;20(10):2016-2025. doi: 10.1158/1535-7163.MCT-20-0987. Epub 2021 Aug 05. PMID: 34353895.
Copy Download .nbib Format: NLM
Dermoscopy as a Noninvasive Diagnostic Modality in Erythromelanosis Follicularis Faciei et Colli: A Case Series.

Dermatology practical & conceptual

Rather S, Shah AA, Shah FY.
PMID: 33747629
Dermatol Pract Concept. 2021 Mar 08;11(2):e2021020. doi: 10.5826/dpc.1102a20. eCollection 2021 Mar.

No abstract available.

Cite
Rather S, Shah AA, Shah FY. Dermoscopy as a Noninvasive Diagnostic Modality in Erythromelanosis Follicularis Faciei et Colli: A Case Series. Dermatol Pract Concept. 2021;11(2):e2021020doi: 10.5826/dpc.1102a20.
Rather, S., Shah, A. A., & Shah, F. Y. (2021). Dermoscopy as a Noninvasive Diagnostic Modality in Erythromelanosis Follicularis Faciei et Colli: A Case Series. Dermatology practical & conceptual, 11(2), e2021020. https://doi.org/10.5826/dpc.1102a20
Rather, Shagufta, et al. "Dermoscopy as a Noninvasive Diagnostic Modality in Erythromelanosis Follicularis Faciei et Colli: A Case Series." Dermatology practical & conceptual vol. 11,2 (2021): e2021020. doi: https://doi.org/10.5826/dpc.1102a20
Rather S, Shah AA, Shah FY. Dermoscopy as a Noninvasive Diagnostic Modality in Erythromelanosis Follicularis Faciei et Colli: A Case Series. Dermatol Pract Concept. 2021 Mar 08;11(2):e2021020. doi: 10.5826/dpc.1102a20. eCollection 2021 Mar. PMID: 33747629; PMCID: PMC7943227.
Copy Download .nbib Format: NLM
Showing 1729 to 1734 of 1734 entries